Global Hidradenitis Suppurativa Market - 2023-2030
The Global Hidradenitis Suppurativa Market reached US$ 725.6 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.1 billion by 2030. The Global Hidradenitis Suppurativa Market is expected to exhibit a CAGR of 4.8% during the forecast period 2023-2030.
Dermatologists and Dermatologic surgeons are among the healthcare experts who diagnose and treat hidradenitis suppurative patients. They determine the condition's severity, recommend the proper therapies (such as antibiotics, anti-inflammatory medications, and immunosuppressants), and offer instructions on how to treat wounds and manage pain.
Market Dynamics
Active key players are boosting the global hidradenitis suppurativa market growth during the forecast period.
Active key players and approval by the government drive the market. For instance, in June 2023, The European Commission (EC) authorized Cosentyx (secukinumab) by Novartis for use in individuals with active moderate to severe hidradenitis suppurative who have not responded adequately to standard systemic hidradenitis suppurative therapy.
More than 1 million people have received treatment with Cosentyx worldwide. The company offers Cosentyx as a well-respected therapy option, providing hidradenitis suppurative sufferers with quick and long-lasting symptom alleviation.
Novartis is well-positioned to facilitate quick and extensive access to Cosentyx because of its well-established patient assistance and market access programs. This milestone approval represents a significant advancement in our goal of providing high-quality medications that address urgent medical needs.
An increasing number of patients with hidradenitis suppurativa is boosting the Global Hidradenitis Suppurativa Market growth during the forecast period.
As per the article published in Clinical Dermatology Review in 2022, hidradenitis suppurativa is more prevalent than previously believed, with an estimated population prevalence of 1% to 4%. The right estimation of the occurrence of hidradenitis suppurativa is further complicated by misdiagnosis and a lack of precise demographic statistics.
After puberty, hidradenitis suppurativa frequently develops, with most individuals experiencing symptoms in their 20s and 30s. When it comes to case distribution, women predominate. The effectiveness of various biologic drugs in the treatment of hidradenitis suppurativa has started to be investigated due to the widespread adoption of the biologic agent adalimumab (ADA) as a first-line therapeutic agent.
Industry-academia partnership provides Global Hidradenitis Suppurativa Market growth opportunities.
For instance, in March 2022, Almirall, S.A., a multinational biopharmaceutical business specializing in skin health, partnered with the University of Michigan to advance knowledge of the triggers of the chronic, inflammatory skin disorder hidradenitis suppurativa.
Through this collaboration, Dr. Johann E. Gudjonsson's dermatology department at the University of Michigan and Almirall's expertise in skin disorders will be merged to study essential features of this illness, such as chronic disease dissection and fibrosis.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the Hidradenitis Suppurativa market. Numerous healthcare professionals have utilized telemedicine and virtual care platforms to reduce the risk of Covid-19 transmission. Although these technologies offer a different communication channel between patients and medical staff, they might not be the best option for all facets of HS management, particularly when physical examinations and procedures are required.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the hidradenitis suppurativa market is complex and multifaceted. Access to healthcare may be hampered during periods of unrest and violence. Healthcare workers may be relocated or occupied with emergency treatment, while hospitals and medical facilities may be damaged or inaccessible. This may affect HS diagnosis, treatment, and management for people living in the impacted locations.
Segment Analysis
The Global Hidradenitis Suppurativa Market is segmented based on clinical stage, skin condition, treatment type, route of administration, end-user, distribution channel, and region.
The medications segment is expected to hold a dominant position in the market over the forecast period.
The medications segment had the highest market stake, accounting for approximately 32.5% of the Hidradenitis Suppurativa market in 2022. If tests reveal a bacterial infection and lumps that are extremely painful, inflamed, and leaking pus, then you may be given a 1- or 2-week course of antibiotics. Low doses of antibiotics may be used to stop inflammation if bacterial infection is absent. A longer course of antibiotics will be taken for at least three months to lessen the number of lumps that form.
Antibiotics can be administered orally, topically (as a cream), or as tablets, capsules, or liquids. Lymecycline, doxycycline, erythromycin, and clarithromycin are different antibiotic kinds. Clindamycin and rifampicin together are beneficial in treating severe cases of hidradenitis suppurativa.
Geographical Analysis
Increasing collaborations and partnerships among the key players and advancement in hidradenitis suppurativa dominate the European region.
Europe is expected to dominate secondly the hidradenitis suppurativa market, accounting for around 25.5% of this market. For instance, in February 2023, Povorcitinib (previously INCB54707) is an oral JAK1 inhibitor that Incyte has reported new 52-week findings from a Phase 2 study examining its effectiveness and safety in treating adult patients with hidradenitis suppurative (HS).
The study previously met its primary endpoint, showing that at Week 16 of the double-blind, placebo-controlled phase, patients receiving povorcitinib once daily (QD) had significantly greater decreases from baseline in Abscess and Inflammatory Nodule (AN) count compared to placebo (least squares mean change, 2.5 [0.9], placebo vs. 5.2 [0.9], P=0.0277, povorcitinib 15 mg; 6.9.
Competitive Landscape
The major global players in the market include Pfizer Inc., Eli Lilly and Company, AbbVie Inc., UCB S.A., Incyte Corporation, Novartis AG, Boehringer Ingelheim, Aclaris Therapeutics, Inc., InflaRx N.V., and Moonlake Immunotherapeutics among others.
Why Purchase the Report?
• To visualize the Global Hidradenitis Suppurativa Market segmentation based on the clinical stage, skin condition, treatment type, route of administration, end-user, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous hidradenitis suppurativa market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Hidradenitis Suppurativa Market Report Would Provide Approximately 85 Tables, 93 Figures And 200+ Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Clinical Stage
- 3.2. Snippet by Skin Condition
- 3.3. Snippet by Treatment Type
- 3.4. Snippet by Route of Administration
- 3.5. Snippet by Distribution Channel
- 3.6. Snippet by End-user
- 3.7. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing Prevalence of hidradenitis suppurativa
- 4.1.2. Restraints
- 4.1.2.1. High cost associated with the treatment
- 4.1.3. Opportunity
- 4.1.3.1. Increasing research and development activities
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers’ Strategic Initiatives
- 6.6. Conclusion
- 7. Russia-Ukraine War Analysis
- 8. Artificial Intelligence Analysis
- 9. By Clinical Stage
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Stage
- 9.1.2. Market Attractiveness Index, By Clinical Stage
- 9.2. Hurley Stage 1*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Hurley Stage 2
- 9.4. Hurley Stage 3
- 10. By Skin Condition
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 10.1.2. Market Attractiveness Index, By Skin Condition
- 10.2. Folliculitis*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Pimples
- 10.4. Boils
- 10.5. Deep-Acne
- 10.6. Others
- 11. By Treatment Type
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.1.2. Market Attractiveness Index, By Treatment Type
- 11.2. Surgery*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Medications
- 11.3.1. Biologics
- 11.3.2. Antibiotics
- 11.3.3. Hormonal Therapy
- 11.3.4. Immunosuppressive Drugs
- 11.3.5. Zinc Supplements
- 11.3.6. Retinoids
- 11.3.7. Pain Medication
- 11.4. Photodynamic Therapy (PDT)
- 11.5. Laser Treatment
- 11.6. Others
- 12. By Route of Administration
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.1.2. Market Attractiveness Index, By Route of Administration
- 12.2. Oral*
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 12.3. Parenteral
- 12.4. Others
- 13. By End-user
- 13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.1.2. Market Attractiveness Index, By End-user
- 13.2. Hospitals*
- 13.2.1. Introduction
- 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 13.3. Specialty Clinics
- 13.4. Homecare
- 13.5. Others
- 14. By Distribution Channel
- 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 14.1.2. Market Attractiveness Index, By Distribution Channel
- 14.2. Hospital Pharmacy*
- 14.2.1. Introduction
- 14.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 14.3. Retail Pharmacy
- 14.4. Online Pharmacy
- 14.5. Others
- 15. By Region
- 15.1. Introduction
- 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 15.1.2. Market Attractiveness Index, By Region
- 15.2. North America
- 15.2.1. Introduction
- 15.2.2. Key Region-Specific Dynamics
- 15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 15.2.9.1. The U.S.
- 15.2.9.2. Canada
- 15.2.9.3. Mexico
- 15.3. Europe
- 15.3.1. Introduction
- 15.3.2. Key Region-Specific Dynamics
- 15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 15.3.9.1. Germany
- 15.3.9.2. The U.K.
- 15.3.9.3. France
- 15.3.9.4. Italy
- 15.3.9.5. Spain
- 15.3.9.6. Rest of Europe
- 15.4. South America
- 15.4.1. Introduction
- 15.4.2. Key Region-Specific Dynamics
- 15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 15.4.9.1. Brazil
- 15.4.9.2. Argentina
- 15.4.9.3. Rest of South America
- 15.5. Asia-Pacific
- 15.5.1. Introduction
- 15.5.2. Key Region-Specific Dynamics
- 15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 15.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 15.5.9.1. China
- 15.5.9.2. India
- 15.5.9.3. Japan
- 15.5.9.4. Australia
- 15.5.9.5. Rest of Asia-Pacific
- 15.6. Middle East and Africa
- 15.6.1. Introduction
- 15.6.2. Key Region-Specific Dynamics
- 15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical stage
- 15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Skin Condition
- 15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 15.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 16. Competitive Landscape
- 16.1. Competitive Scenario
- 16.2. Product Benchmarking
- 16.3. Company Share Analysis
- 16.4. Key Developments and Strategies
- 17. Company Profiles
- 17.1. Pfizer Inc.*
- 17.1.1. Company Overview
- 17.1.2. Product Portfolio and Description
- 17.1.3. Financial Overview
- 17.1.4. Key Developments
- 17.2. Eli Lilly and Company
- 17.3. AbbVie Inc.
- 17.4. UCB S.A.
- 17.5. Incyte Corporation
- 17.6. Novartis AG
- 17.7. Boehringer Ingelheim
- 17.8. Aclaris Therapeutics, Inc.
- 17.9. InflaRx N.V.
- 17.10. Moonlake Immunotherapeutics
- LIST NOT EXHAUSTIVE
- 18. Appendix
- 18.1. About Us and Services
- 18.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook